Tony Tramontin Ph.D. serves as Senior Vice President of Research and Development , Chief Scientific Officer of the Company.Dr. Tramontin was a Partner in McKinsey & Company’s Global Healthcare Practice. Across a 13 year career, he advised biopharma executive teams on a wide variety of strategic, operational and organizational topics across the value chain. The majority of his work, however, focused specifically on research, medicine development and early aspects of commercialization. He co-founded and led McKinsey’s technical service line that helps biopharma executives with R&D project investment decisions, portfolio prioritization, risk management, therapeutic area strategy, and product launch strategy. Before joining McKinsey, Dr. Tramontin was an experimental neuroscientist conducting neural stem cell research at The Rockefeller University and in The University of California San Francisco Department of Neurosurgery.
Tony Tramontin is 52, he's been the Senior Vice President of Research and Development a Chief Scientific Officer of Axcella Health Inc since 2017. There are 10 older and 6 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
Tony's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... a Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Axcella Health Inc executives and other stock owners filed with the SEC include: